An EGFR T790M-mutated lung adenocarcinoma undergoing large-cell neuroendocrine carcinoma transformation after osimertinib therapy: a case report

BACKGROUND: Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, is selective for both epidermal growth factor receptor tyrosine kinase inhibitor–sensitizing and T790M resistance mutations. Almost all patients who initially respond to an epidermal growth factor...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Med Case Rep
Autors principals: Miyazaki, Shinichi, Kuno, Yasumasa, Hayai, Shunsaku, Teramachi, Ryo, Yamashita, Ryo, Saito, Yusuke, Higuchi, Kosuke, Nara, Yoshiharu, Ikeda, Takuya
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7412784/
https://ncbi.nlm.nih.gov/pubmed/32762742
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13256-020-02447-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars